Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $2.9 million.

  • Denali Therapeutics' Depreciation & Amortization (CF) rose 60.34% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 25.32%. This contributed to the annual value of $7.8 million for FY2024, which is 53.37% down from last year.
  • Per Denali Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2.9 million for Q3 2025, which was down 3.22% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Depreciation & Amortization (CF) peaked at $10.0 million during Q1 2023, and registered a low of $1.8 million during Q3 2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $2.2 million (2023), whereas its average is $3.0 million.
  • Per our database at Business Quant, Denali Therapeutics' Depreciation & Amortization (CF) spiked by 383.26% in 2023 and then slumped by 78.48% in 2024.
  • Over the past 5 years, Denali Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $2.1 million in 2021, then spiked by 95.53% to $4.1 million in 2022, then slumped by 47.01% to $2.2 million in 2023, then fell by 14.65% to $1.9 million in 2024, then skyrocketed by 60.34% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.0 million for Q2 2025, and $2.3 million during Q1 2025.